Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


CSL closes on gene therapy

Posted 7 May 2021 AM

CSL has announced it will pay Dutch biotech uniQure an upfront cash payment of US$450 million for its investigational haemophilia B gene therapy next week with antitrust reviews of the transaction now complete in the US, the UK and Australia.

The treatment, dubbed etranacogene dezaparvovec, has the potential to be the first-ever gene therapy approved for haemophilia B says CSL CEO and managing director Paul Perreault who announced the company's plans to acquire the therapy in mid-2020.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options